首页> 外文期刊>Seminars in fetal & neonatal medicine >Stem cell medicine: umbilical cord blood and its stem cell potential.
【24h】

Stem cell medicine: umbilical cord blood and its stem cell potential.

机译:干细胞医学:脐带血及其干细胞潜力。

获取原文
获取原文并翻译 | 示例
       

摘要

The ultimate aim of stem cell research is to improve patient outcomes and quality of life, and/or to effect a cure for a variety of inherited or acquired diseases. Improved treatments rely on developments in stem cell therapies and the discovery of new therapeutic drugs that regulate stem cell functions. These complement each other for the repair, regeneration and replacement of damaged or defective tissues. Stem cells may be sourced or derived from blood and tissues postnatally ('adult' stem cells), from the fetus (fetal stem cells) or from the blastocyst in the developing embryo prior to implantation (embryonic stem cells), each forming a unique component of the revolution in stem cell research and therapies. This review will concentrate on recent developments in the use of haemopoietic stem cells from umbilical cord blood for the transplantation of patients with haematological disorders. It will conclude with a summary of the potential of other umbilical cord blood-derived stem cells for tissue repair or regeneration.
机译:干细胞研究的最终目的是改善患者的预后和生活质量,和/或治愈各种遗传性或后天性疾病。改进的治疗方法依赖于干细胞疗法的发展以及调节干细胞功能的新型治疗药物的发现。这些相互补充,以修复,再生和更换受损或有缺陷的组织。干细胞可能来源于或来源于出生后的血液和组织(“成人”干细胞),胎儿(胎儿干细胞)或植入前发育中胚胎的胚泡(胚性干细胞),每个都形成独特的成分干细胞研究和疗法革命的历史。这篇综述将集中在使用脐带血造血干细胞移植血液病患者的最新进展。最后将总结其他脐带血干细胞在组织修复或再生中的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号